Skip to main content
BVS logo

BVS · Bioventus Inc.

Track BVS — free
$10.41 -0.21 (-1.98%)
Market Cap
$894.85M
Shares
84.26M
Volume · Nov 18 697.31K Avg daily vol (3M) 538.57K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.62 Open$10.60 Day$10.51–11.01 52W close$6.53–15.26 Avg vol 30d590K Short int3.0M · 3.6% of shares · 6.6d Short vol56% Last earningsNov 2, 2026 DataFeb 2021–Nov 2026 Filing10-Q · Nov 2

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 2
Earnings call
Revenue guidance cut as BGS weakness persists

Bioventus lowered 2026 revenue guidance to $590 million to $595 million, primarily due to weaker BGS expectations, while reaffirming adjusted EPS guidance of $0.75 to $0.79 and adjusted operating cash flow guidance of $84 million to $89 million.

4 source passages
Bioventus continued to build on its positive momentum in the third quarter. As a result of strong earnings and outlook for the business, we are reaffirming our full-year adjusted earnings per share guidance of $0.75 to $0.79 per diluted share. We are adjusted, or previously provided, cash from operations guidance of $84 million to $89 million, and presenting adjusted cash from operations in the same range, which excludes the cash flow impact of the company's review of potential strategic alternatives. With lower revenue expectations, primarily in BGS, we now expect 2026 revenue of $590 million to $595 million. Open the document at this passage
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 26
Nine-month sales and Adjusted EBITDA rise

Bioventus reported nine-month net sales of 427,739 and Adjusted EBITDA of 87,534, in thousands, for the period ended September 26, 2026; sales increased 4.3%. Discretionary term-loan prepayments totaled $57.0 million, and interest expense decreased $9.0 million.

Revenue $142.44M ▲ 2.7% Net income $5.99M ▲ 89.8% Diluted EPS $0.08 ▲ 60.0%
Read from the MD&A section
6 source passages
The following discussion and analysis of Bioventus Inc.’s (sometimes referred to as “we,” “us,” “our,” “Bioventus” or “the Company”) financial condition and results of operations Nine Months Ended | | September 26, 2026 | September 27, 2025 | | Net sales | 427,739 | 410,187 | Nine Months Ended | | September 26, 2026 | September 27, 2025 | | Adjusted EBITDA | 87,534 | 79,567 | | Total net sales | 427,739 | 410,187 | 17,552 | 4.3% | During the nine months ended September 26, 2026, we made total principal payments of $64.5 million on the 2025 Term Loan, consisting of two scheduled quarterly payments of $3.75 million and three discretionary payments totaling $57.0 million. Interest expense, net decreased $9.0 million during the nine months ended September 26, 2026 compared to the prior year period, primarily due to lower debt outstanding and reduced interest rates and applicable margins. Open the document at this passage
Nov 2
Current report 8-K
Q3 revenue up 3% to $142.4 million as strategic review continues

Bioventus reported third-quarter revenue of $142.4 million, up 3%, with GAAP diluted EPS of $0.08 versus $0.05 a year earlier, and continues to review potential strategic alternatives.

Financial results
3 source passages
For the third quarter, worldwide revenue of $142.4 million advanced 3%, primarily driven by growth in Pain Treatments. GAAP earnings of $0.08 per diluted share of Class A common stock improved from $0.05 per diluted share in the prior-year period. At the same time, we continue to review potential strategic alternatives for the Company Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 27
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $153.21M ▲ 3.8% Net income $33.44M ▲ 348.3% Diluted EPS $0.47 ▲ 327.3%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$585.64M
Trailing 12 months
Net income (TTM)
$57.30M
Trailing 12 months
Revenue growth YoY
+2.7%
Year over year
Operating margin
9.7%
Trailing 12 months
P / E (TTM)
13.3
Trailing earnings · reciprocal yield 7.5%
FCF yield
9.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$199.12M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.3%
Year over year · more shares
Price change (1Y)
+51.9%
Trailing year
Short interest
3.6%
Latest settlement · 6.6 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Bioventus reported Q2 revenue of $153.2 million (up 4%) driven by double-digit Pain Treatments growth, reaffirmed full-year 2026 guidance, made a $20 million discretionary debt prepayment, and initiated a review of strategic alternatives following an unsolicited acquisition proposal.

Bullish
  • + Made a $20.0 million discretionary principal prepayment on term loan, with debt pay down of $46 million YTD and leverage below 2x
  • + Board initiated review of strategic alternatives following unsolicited acquisition proposal and multiple expressions of interest
  • + PRP and PNS businesses showed accelerated capital placements, new customer wins, and positive market feedback
Bearish
  • − Company took proactive channel actions in BGS during Q2 that had a temporary impact on the business

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −4%
below
Price vs 50-day avg −18%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 47%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −25%
trailing
6-month return +25%
trailing
YTD return +43%
this year
Relative strength +28%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $13 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.59% of shares out · ▼ -4.9% MoM · 6.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
170 holders — near 3-yr high, broad support
Squeeze score 55
elevated · 0–100
Fundamentals
Strong
Revenue growth −1%
Y/Y
Gross margin 68%
expanding
EPS growth +159%
Y/Y
Free cash flow $72.1M
Valuation P/E 13.3
below peers
Balance sheet $242.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 53%
annualized · 1-yr
Max drawdown −31%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 5
Latest guidance · from the 8-K filed Nov 2, 2026
Adjusted EPS · For the twelve months ending December 31, 2026 Maintained $0.75 – $0.79
Aug 5, 2026 $0.75 – $0.79 changed to Nov 2, 2026 $0.75 – $0.79
Adjusted Cash from Operations · For the twelve months ending December 31, 2026 $84M – $89M
Net Sales · For the twelve months ending December 31, 2026 Lowered $590M – $595M
Aug 5, 2026 $600M – $610M changed to Nov 2, 2026 $590M – $595M
prior FY $568.09M midpoint +4.3% Y/Y
Growth · For the twelve months ending December 31, 2026 4% – 5%
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Cash from operations · 2026 $84M – $89M
Guided vs delivered · last 5 settled
Net sales twelve months ending December 31, 2025
guided $560M – $570M
$568.09M In line
Net sales full-year 2024
guided $535M – $550M
$573.28M Beat +5.7%
Net sales twelve months ending December 31, 2023
guided $498M – $505M
$512.35M Beat +2.2%
Net sales twelve months ending December 31, 2022
guided $527M – $532M
$512.12M Miss −3.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−4% Neutral
Price vs 50-day avg
−18% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
47% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $13 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.59% of shares out · ▼ -4.9% MoM · 6.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
170 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $11 · 47% Range high $15
vs 200-day avg -4% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP 35.3M Q2 2026 —
International Segment Adjusted EBITDA non-GAAP $4.78M Three Months Ended June 27, 2026 filing —
U.S. Segment Adjusted EBITDA non-GAAP $30.49M Three Months Ended June 27, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BVS
Bioventus Inc.
this stock
$894.85M +42.7% -0.9% 13.3 3.6%
ABT
Abbott Laboratories
$180.95B -16.6% +5.7% 39.0 1.1%
MDT
Medtronic plc
$128.83B +4.9% +8.4% 24.8 1.8%
SYK
Stryker Corp
$121.12B -9.5% +11.2% 33.9 1.7%
BSX
Boston Scientific Corp
$63.26B -54.2% +12.5% 18.5 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
170
% held
68.0%
Net QoQ
+3.5M sh
Top holder
Essex Woodlands Managemen…
Held Float
View
Held by Funds
Fund positions
172
View
Short & Settlement
Short Interest Falling
Shares short
3.0M
Days to cover
6.6d
Change
-154.9K sh
View
Short Volume
Short vol %
56%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
312
Value
$4.7K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
36.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$568.1M
Net income (FY)
$22.7M
EPS diluted
$0.33
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 2, 2026
This year
14

Bioventus reported nine-month net sales of 427,739 and Adjusted EBITDA of 87,534, in thousands, for the period ended September 26, 2026; sales increased 4.3%. Discretionary term-loan prepayments totaled $57.0 million, and interest expense decreased $9.0 million.

View
Proposed Sales
Value
$105.7K
Shares
12.0K
Filed
Mar 11, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 2, 2026
View
Investor Relations
Latest news
Bioventus Reports Third Quarter F…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
BVS -3.4% -25.4% +24.8% -20.3% +42.7%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +0.5% -19.9% +28.3% -16.9% +35.7%
Key facts CIK 1665988 CUSIP 09075A108 13F (30d) 172 filings 157 filers Visit website Investor relations